AEROSEB-DEX Drug Patent Profile
✉ Email this page to a colleague
When do Aeroseb-dex patents expire, and when can generic versions of Aeroseb-dex launch?
Aeroseb-dex is a drug marketed by Allergan Herbert and is included in one NDA.
The generic ingredient in AEROSEB-DEX is dexamethasone. There is one drug master file entry for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aeroseb-dex
A generic version of AEROSEB-DEX was approved as dexamethasone by PANGEA on April 28th, 1983.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AEROSEB-DEX?
- What are the global sales for AEROSEB-DEX?
- What is Average Wholesale Price for AEROSEB-DEX?
Summary for AEROSEB-DEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 109 |
| Patent Applications: | 4,682 |
| DailyMed Link: | AEROSEB-DEX at DailyMed |
US Patents and Regulatory Information for AEROSEB-DEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Herbert | AEROSEB-DEX | dexamethasone | AEROSOL;TOPICAL | 083296-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for AEROSEB-DEX
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| AbbVie Deutschland GmbH & Co. KG | Ozurdex | dexamethasone | EMEA/H/C/001140Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy. | Authorised | no | no | no | 2010-07-26 | |
| THERAVIA | Neofordex | dexamethasone | EMEA/H/C/004071Treatment of multiple myeloma. | Authorised | no | no | no | 2016-03-16 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
